Microbiota Q&A Series – Probiotics International Ltd (Protexin)
Who are you? What do you do? Tell our readers about your company.
We are Probiotics International Ltd based in the UK and a manufacturer of Probiotics formulations for humans and animals for over 25 years.
What does your company bring to the industry?
Our purpose-built manufacturing facilities are cGMP certified by the MHRA. Specialising in the Probiotic manufacturing industry and supplying over 90 countries including the UK, EU, US and Australia, we have extensive experience in registration requirements in many countries worldwide. We also have experience of placing products directly onto the market as well as business to business customers. Our employee skills also include new product development, marketing and sales.
What exciting changes have you experienced in your time in the industry?
The regulatory requirements for Probiotics as Food Supplements in the UK, in contrast to the para-medicinal classification in other countries, along with our customer base expectations has required us to work to continuously improve our manufacturing and product formulation as well as research standards. The customer need and expectation for published clinical trial evidence has motivated us to meet with this changing expectation.
What’s the next big challenge for LBP’s and Microbiotic Medicinal Products?
Establishing guidelines so that we understand the expectation on our processes in order to meet with appropriate medicinal requirements.
In your opinion, what should be everyone’s priority for pushing this industry forward?
Raising the standards in all areas of product formulation, manufacturing and research and communicating these improvements to the final consumer so that they have confidence in product efficacy and quality standards.
What areas of medicine will soon involve the human microbiome?
Personal preventative medicine including LBPs.
Where do you see the science of the human microbiome in the next 5 years?
At the consumer level, such that an individual will be able to utilise the technology to individualise medicines.
What can we look forward to from your company? Anything in your pipeline that you can share with our readers?
High standards of product specific clinical trials combined with high standards in quality.